Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexvax2 Safety and Tolerability in Celiac Disease
NCT02528799Phase 1Completed
- Sponsor
- ImmusanT
- Start
- Aug 2015
- Primary completion
- Jan 2017
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of nexvax2 in celiac disease (6 arms), sponsored by ImmusanT. Primary endpoint: Incidence of toxicity and safety of Nexvax2. Started Aug 2015; status: completed.
02
Drugs
nexvax2
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT02528799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528799.